August 9, 2017 / 3:10 PM / in a year

BRIEF-Mylan gives details on genric approval processes

Aug 9 (Reuters) - Mylan NV

* Says disappointed with the execution by FDA on approval process of generic Copaxone

* Says no further clinical or device-related studies are required for generic Advair approval process

* Says will be opportunistic on deal opportunities to fill product or geographic gaps Further company coverage: (Reporting By Michael Erman)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below